Observational studyJournal of neurology2018
Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study.
Observational study in Journal of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Rituximab for people with multiple sclerosis.The Cochrane database of systematic reviews · 2025Pooled it
- Rituximab in secondary progressive multiple sclerosis: a meta-analysis.Annals of clinical and translational neurology · 2024Pooled it
- Efficacy and safety of rituximab in multiple sclerosis: a systematic review and meta-analysis.Acta neurologica Belgica · 2023Pooled it
- Rituximab for people with multiple sclerosis.The Cochrane database of systematic reviews · 2021Pooled it
- B cell CD19 is transferred between immune cells in mice and humans.Nature communications · 2026Article
- Investigating mechanisms underlying the development of paralysis symptom in a model of MS.Brain research bulletin · 2025Article
- Long-Term Adverse Events of Rituximab in Multiple Sclerosis Patients, Isfahan, Iran.International journal of preventive medicine · 2025Article
- Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis.BMC health services research · 2023Article
- Assessing Sustained B-Cell Depletion and Disease Activity in a French Multiple Sclerosis Cohort Treated by Long-Term IV Anti-CD20 Antibody Therapy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Article
- Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience.Frontiers in neurology · 2023Article
- Adverse drug reactions of Rituximab in patients suffering from autoimmune neurological diseases.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2022Observational
- Delayed B cell repopulation after rituximab treatment in multiple sclerosis patients with expanded adaptive natural killer cells.European journal of neurology · 2022Observational
- Efficacy and safety of rituximab in patients with multiple sclerosis: An observational study at a tertiary center in Makkah, Saudi Arabia.Neurosciences (Riyadh, Saudi Arabia) · 2022Observational
- Anti-CD20 therapies for multiple sclerosis: current status and future perspectives.Journal of neurology · 2022Review
- Effect of Rituximab on the cognitive impairment in patients with secondary progressive multiple sclerosis.Caspian journal of internal medicine · 2022Article
- Rituximab for the treatment of multiple sclerosis: a review.Journal of neurology · 2022Review
- RituximabTherapeutic advances in chronic disease · 2021Article
- Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?Frontiers in immunology · 2021Review
- Experience with rituximab therapy in a real-life sample of multiple sclerosis patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020Article
- Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.Annals of clinical and translational neurology · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRituximab is considered as a potential therapeutic option in relapsing-remitting (RRMS) and progressive forms (PMS) of multiple sclerosis (MS).
objectiveTo investigate the effectiveness and safety of rituximab in MS. PATIENTS AND
methodsObservational study of effectiveness (clinical and radiological) and safety of rituximab in RRMS and PMS.
resultsA total of 90 rituximab-treated patients were collected: 31 RRMS and 59 PMS All patients had an active disease despite standard treatment. The annualized relapse rate (ARR) the year before rituximab was 0.86, 53.3% of patients had gadolinium enhanced lesion, and mean Expanded Disability Status Scale (EDSS) had increased from 4.2 to 4.9. During treatment, the ARR was reduced an 88.4% (p < 0.001). A significant decrease of EDSS to 4.6 was observed (p = 0.01) after 1 year of treatment, which remained stable during the second year in both groups. There was no evidence of disease activity in 70% of total sample, 74.2% of RRMS, and 67% of the PMS patients. Infusion-related symptoms were the most prevalent side effect (18.8%) and most were mild. Three thrombotic events were detected.
conclusionRituximab could be an effective and safe treatment in aggressive RRMS. Some selected PMS patients could also benefit from this treatment.
Indexed as
Identifiers
29785523What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.